CHICAGO - A decade ago, pharma firms maintained "an aloof attitude" toward struggling biotechs, condescending to make deals only when the aims of the deep-pocketed savior meshed clearly and perfectly with an early stage innovator, noted Steve Kuemmerle, director of Abbott Biotech Ventures. "Now, we all kind of think we're in the same boat," he said. Read More
